Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
Completed
AbbVie (prior sponsor, Abbott)
Phase 3
2008-02-01
The primary purpose of this study is to test the effect and safety of once daily ABT-335 on
the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients
with abnormal blood lipids who have optimal levels of low density lipoprotein cholesterol
("bad cholesterol") after taking atorvastatin.
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
Completed
Abbott
Phase 3
2008-02-01
The primary purpose of this study is to compare the safety and efficacy of ABT-335
(investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin
coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
Completed
Radiant Research
Phase 1/Phase 2
2008-03-01
The objectives of the study are:
1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT
(reverse cholesterol transport) in men and post-menopausal women diagnosed with
dyslipidemia (i.e., low high-density lipoprotein [HDL] cholesterol levels and elevated
triglyceride [TG] concentrations).
2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL.
3. To obtain pilot data for power calculations for subsequent comparative study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
